Bronchoscopic local instillation of amphotericin B deoxycholate as adjunctive therapy for pulmonary mucormycosis with inadequate response to posaconazole: a retrospective case series - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Endobronchial Administration of Amphotericin B Deoxycholate as an Adjunctive Treatment for Pulmonary Mucormycosis Unresponsive to Posaconazole: A Retrospective Case Review

  • By

  • Liyan Qiu

  • Binyue Liang

  • Hua Zhou

  • August 17, 2026

Share

  • 1

    Pulmonary mucormycosis is a severe fungal infection primarily affecting immunocompromised individuals, often requiring systemic antifungal therapy.

  • 2

    A retrospective review identified five patients with pulmonary mucormycosis who did not respond adequately to posaconazole-based therapy.

  • 3

    Patients underwent bronchoscopic airway clearance followed by local administration of amphotericin B deoxycholate, with no reported adverse events.

  • 4

    Follow-up CT scans showed partial absorption or shrinkage of pulmonary lesions in all five patients after local amphotericin B treatment.

  • 5

    The study suggests that local amphotericin B deoxycholate may be a feasible adjunctive treatment for pulmonary mucormycosis unresponsive to posaconazole.

Original Source(s)

Bronchoscopic local instillation of amphotericin B deoxycholate as adjunctive therapy for pulmonary mucormycosis with inadequate response to posaconazole: a retrospective case series

  • by Liyan Qiu, Binyue Liang, Hua Zhou

  • August 17, 2026

Related Content

Correction: Acute retinal necrosis presenting exudative retinal detachment: a case report

Correction: The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations

Counterfactual evaluation of COVID-19 control policies in South Korea: A scenario-based modeling study